Biomarkers, Genomics, Physiology in Critically Ill and ECMO Patients — IGNITE  

Critical Illness Clinical Trial

Official title: Investigation of Biomarkers, Genomics, Physiology in Critically Ill and ECMO Patients

Status Active, not recruiting

Clinical Trial Summary

Patients in end-stage cardiac failure and/or respiratory failure may be started on a rescue therapy known as Extracorporeal Membrane Oxygenation (ECMO). One of the major clinical questions is how to manage the ventilator when patients are on ECMO therapy. Ventilator Induced Lung Injury (VILI) can result from aggressive ventilation of the lung during critical illness. VILI and lung injury such as Acute Respiratory Distress Syndrome (ARDS) can further increase the total body inflammation and stress, this is known as biotrauma. Biotrauma is one of the mechanisms that causes multi-organ failure in critically ill patients. One advantage of ECMO is the ability to greatly reduce the use of the ventilator and thus VILI by taking control of the patient's oxygenation and acid-base status. By minimizing VILI during ECMO we can reduce biotrauma and thus multi-organ failure. Since the optimal ventilator settings for ECMO patients are not known, we plan to study the impact of different ventilator settings during ECMO on patient's physiology and biomarkers of inflammation and injury.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Respiratory Distress Syndrome
• Cardiac Failure
• Critical Illness
• Extracorporeal Membrane Oxygenation Complication
• Heart Failure
• Pulmonary Disease
• Renal Failure
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn
• Respiratory Failure
• Respiratory Insufficiency

• NCT number: NCT04669444
• Study type: Interventional
• Source: University of California, San Diego
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 14, 2020
• Completion date: March 1, 2023